Palatin Technologies, Inc. Reports Fourth Quarter And Fiscal Year 2016 Results
CRANBURY, N.J., Sept. 20, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for its fourth quarter and fiscal year ended June 30, 2016. Significant Highlights Bremelanotide – Under development […]
Palatin Technologies, Inc. Reports Fourth Quarter And Fiscal Year 2016 Results Read More »